Sage Therapeutics. has filed a patent for neuroactive steroids that act as GABA modulators, potentially inducing sedation and anesthesia. The patent includes compounds of Formula (I) and their pharmaceutical compositions. Claims 1-66 have been canceled. GlobalData’s report on Sage Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Sage Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Sage Therapeutics, Anti-inflammatory anesthetics was a key innovation area identified from patents. Sage Therapeutics's grant share as of January 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.

The patent application (Publication Number: US20240025942A1) discloses a series of claims related to a compound of Formula (I) and its pharmaceutical applications. The compound or pharmaceutically acceptable salt of the formula is described with specific variations in the alkyl groups R1 and R2. The patent claims cover the use of this compound in treating CNS-related disorders associated with GABA function, including but not limited to sleep disorders, mood disorders, epilepsy, tremors, and anxiety disorders. The method of treatment involves administering the compound orally, intravenously, or intramuscularly, either alone or in combination with other therapeutic agents.

Furthermore, the patent application extends the potential applications of the compound to induce sedation and/or anesthesia in subjects in need thereof. The method involves administering a therapeutically effective amount of the compound or its pharmaceutically acceptable salt to achieve the desired sedative or anesthetic effects. The patent claims encompass various CNS-related disorders and conditions where the compound shows promise as a treatment option, highlighting its versatility and potential in addressing a wide range of neurological and psychiatric conditions. The administration of the compound can be chronic and may involve combination therapy with other agents to enhance efficacy in managing the specified disorders.

To know more about GlobalData’s detailed insights on Sage Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies